Stem cell therapies have many potential uses. If seeking treatment with stem cells, it is advisable to confirm FDA oversight of the treatment or clinical trial.
Dr. Christopher Rogers is the Medical Director of Personalized Stem Cells, Inc. An expert in Regenerative Medicine with more than twenty-five years of clinical experience, Dr. Rogers is one of the investigators in PSC’s first FDA approved clinical trial.
On April 27, 2020 PSC CEO, Dr. Bob Harman and PSC Medical Director, Dr. Christopher Rogers, were interviewed by San Diego CBS affiliate, KFMB TV, regarding stem cell therapy for COVID-19.
Personalized Stem Cells, Inc. (PSC) has filed a request for expedited review of an FDA Investigational New Drug (IND) for the treatment of COVID-19 patients with stem cells. PSC is accepting donations to meet the stem cell production needed to provide treatments for COVID-19 patients.
Personalized Stem Cells, Inc. and Calidi Biotherapeutics collaborate to rapidly bring a stem cell therapy into clinical trials for COVID-19 patients.
Stem cells utilize multiple modes of action to aid healing.
In October, Personalized Stem Cells (PSC) was a primary sponsor of an event put on by the Arthritis Foundation in Los Angeles, California.
Personalized Stem Cells Co-Founder and Chief Scientific Officer, Dr. Bob Harman, will be a panelist in a discussion about Optimizing Cell Product Development and Delivery to Patients at the upcoming CTTACC conference.
The FDA has the authority to regulate stem cell therapies in the United States. In July of 2019, PSC announced the FDA approval of their IND to treat osteoarthritis with autologous adipose-derived stem cell therapy through clinical trials.
Autologous Adipose-Derived Stem Cell Therapy is a medical therapy used to treat orthopedic conditions.